DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Memantine for Enhanced Stroke Recovery

Information source: University of Utah
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Ischemic Stroke; Upper Extremity Weakness

Intervention: Memantine (Drug); Placebo (for memantine) (Drug)

Phase: Phase 0

Status: Recruiting

Sponsored by: University of Utah

Official(s) and/or principal investigator(s):
Alicia Bennett, D.O., Principal Investigator, Affiliation: University of Utah
Jennifer Majersik, M.D., Principal Investigator, Affiliation: University of Utah

Overall contact:
Alicia Bennett, D.O., Phone: 801-585-2033, Email: alicia.bennett@hsc.utah.edu

Summary

This will be a randomized double blind placebo-controlled pilot study using a repeated measures design in which participants with acute ischemic stroke and upper extremity weakness are randomized to either drug or placebo, complete therapy, and complete outcomes assessments at baseline, 4, and 12 weeks post-stroke. Target enrollment will be 10 patients per group and adaptive randomization will be used to assist with equal representation of pre-stroke selective serotonin reuptake inhibitor (SSRI) use and motor severity (Fugl-Meyer score) in each arm. The primary purpose of this pilot study is to measure adverse events, drop-out rates, feasibility of trial conductance, and establishment of effect sizes in each group in order to power a larger efficacy trial at the University of Utah. An intention to treat model will be used during the study.

Clinical Details

Official title: Pilot Study of Memantine for Enhanced Stroke Recovery

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Fugl-Meyer Assessment

Fugl-Meyer Assessment

Adverse events

Adverse Events

Secondary outcome:

Motor Activity Log (MAL)

Motor Activity Log (MAL)

Ten Meter Walk Test

Ten Meter Walk Test

Stroke Impact Scale (SIS)

Stroke Impact Scale (SIS)

Cancellation Tests

Cancellations Tests

Grip Strength Test

Grip Strength Test

Montreal Cognitive Assessment (MoCA©)

Montreal Cognitive Assessment (MoCA©)

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Age 18-80 years old 2. Randomization between 3-8 days of stroke symptom onset 3. Arm weakness severe enough to warrant inpatient or outpatient occupational therapies 4. Able to voluntarily move the wrist or a digit of the affected UE 5. Living independently prior to their stroke 6. Image-confirmed ischemic stroke (MRI or CT) 7. Supratentorial location of stroke 8. Fugl-Meyer Score of 55 or less 9. Ability to swallow pills Exclusion Criteria: 1. Hemorrhagic stroke, subarachnoid hemorrhage, or other cause of symptoms other than ischemic stroke 2. Infratentorial location of stroke (brainstem or cerebellum) 3. NIH Stroke Scale >20 at the time of randomization 4. History of dementia that will interfere with rehabilitation 5. Pre or post-stroke use of memantine or amantadine 6. Contraindications to taking memantine in pill form 7. History of prior clinical stroke 8. Documented severe renal impairment (CrCl < 30 ml/min) Blood tests will be performed prior to study procedures that will ensure patients do not have renal impairment if not done as part of clinical care. 9. Moribund or not expected to live 6 months 10. Severe cognitive deficits or pre-morbid function causing inaccurate neurologic assessment or inability to complete the initial assessment 11. Comorbid neurologic disease that would interfere with the results including but not limited to Multiple Sclerosis, neurodegenerative diseases, spinal cord disease, and central nervous system cancer. 12. Documented severe hepatic impairment (Child-Pugh score > 6) or severe hepatic disease (hepatitis) 13. Patients who are pregnant or breast feeding

Locations and Contacts

Alicia Bennett, D.O., Phone: 801-585-2033, Email: alicia.bennett@hsc.utah.edu

University of Utah, Salt Lake City, Utah 84132, United States; Recruiting
Alicia Bennett, D.O., Principal Investigator
Jennifer Majersik, M.D., Principal Investigator
Lorie Richards, Ph.D., OTR/L, Sub-Investigator
Jana Wold, M.D., Sub-Investigator
Dana DeWitt, M.D., Sub-Investigator
Peter Hannon, M.D., Sub-Investigator
Aleks Tkach, M.D., Sub-Investigator
Tina Burton, M.D., Sub-Investigator
Kevin Brennan, M.D., Sub-Investigator
Julie Martinez, RN, Sub-Investigator
Suyi Niu, Sub-Investigator
Haimei Wang, Sub-Investigator
Steve Edgley, M.D., Sub-Investigator
Edward DiBella, PhD, Sub-Investigator
Abby DeLawder, Sub-Investigator
Connie Keith, Sub-Investigator
Gina McDonald, Sub-Investigator
David Scott, Sub-Investigator
Christopher Walter, Sub-Investigator
Additional Information

Related publications:

Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013 Jan 1;127(1):143-52. doi: 10.1161/CIR.0b013e318282ab8f. Review.

Rathore SS, Hinn AR, Cooper LS, Tyroler HA, Rosamond WD. Characterization of incident stroke signs and symptoms: findings from the atherosclerosis risk in communities study. Stroke. 2002 Nov;33(11):2718-21.

Kalra L, Eade J. Role of stroke rehabilitation units in managing severe disability after stroke. Stroke. 1995 Nov;26(11):2031-4.

Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, Bejot Y, Deltour S, Jaillard A, Niclot P, Guillon B, Moulin T, Marque P, Pariente J, Arnaud C, Loubinoux I. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011 Feb;10(2):123-30. doi: 10.1016/S1474-4422(10)70314-8. Epub 2011 Jan 7. Erratum in: Lancet Neurol. 2011 Mar;10(3):205.

Ziemann U, Ilić TV, Pauli C, Meintzschel F, Ruge D. Learning modifies subsequent induction of long-term potentiation-like and long-term depression-like plasticity in human motor cortex. J Neurosci. 2004 Feb 18;24(7):1666-72. Erratum in: J Neurosci. 2004 Nov 17;24(46):1 p following 10552. Iliać, Tihomir V [corrected to Ilić, Tihomir V].

Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx. 2004 Jan;1(1):101-10. Review.

Chen HS, Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J Physiol. 1997 Feb 15;499 ( Pt 1):27-46.

Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci. 1992 Nov;12(11):4427-36.

Chen HS, Wang YF, Rayudu PV, Edgecomb P, Neill JC, Segal MM, Lipton SA, Jensen FE. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience. 1998 Oct;86(4):1121-32.

Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. Neuropharmacology. 1999 Jun;38(6):735-67. Review.

Kilic U, Yilmaz B, Reiter RJ, Yüksel A, Kilic E. Effects of memantine and melatonin on signal transduction pathways vascular leakage and brain injury after focal cerebral ischemia in mice. Neuroscience. 2013 May 1;237:268-76. doi: 10.1016/j.neuroscience.2013.01.059. Epub 2013 Feb 8.

LUCAS DR, NEWHOUSE JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol. 1957 Aug;58(2):193-201.

Léveillé F, El Gaamouch F, Gouix E, Lecocq M, Lobner D, Nicole O, Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 2008 Dec;22(12):4258-71. doi: 10.1096/fj.08-107268. Epub 2008 Aug 18.

Wenk GL, Zajaczkowski W, Danysz W. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav Brain Res. 1997 Feb;83(1-2):129-33.

Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets. 2001 Sep;2(3):241-71. Review.

Babu CS, Ramanathan M. Pre-ischemic treatment with memantine reversed the neurochemical and behavioural parameters but not energy metabolites in middle cerebral artery occluded rats. Pharmacol Biochem Behav. 2009 May;92(3):424-32. doi: 10.1016/j.pbb.2009.01.010. Epub 2009 Jan 23.

Cho GS, Lee JC, Ju C, Kim C, Kim WK. N-Methyl-D-aspartate receptor antagonists memantine and MK-801 attenuate the cerebral infarct accelerated by intracorpus callosum injection of lipopolysaccharides. Neurosci Lett. 2013 Mar 22;538:9-14. doi: 10.1016/j.neulet.2013.01.031. Epub 2013 Jan 30.

Culmsee C, Junker V, Kremers W, Thal S, Plesnila N, Krieglstein J. Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. Stroke. 2004 May;35(5):1197-202. Epub 2004 Apr 1.

Lapchak PA. Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits. Brain Res. 2006 May 9;1088(1):141-7. Epub 2006 Apr 13.

Montagne A, Hébert M, Jullienne A, Lesept F, Le Béhot A, Louessard M, Gauberti M, Orset C, Ali C, Agin V, Maubert E, Vivien D. Memantine improves safety of thrombolysis for stroke. Stroke. 2012 Oct;43(10):2774-81. Epub 2012 Aug 9.

Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004 Jan 21;291(3):317-24.

Emre M, Tsolaki M, Bonuccelli U, Destée A, Tolosa E, Kutzelnigg A, Ceballos-Baumann A, Zdravkovic S, Bladström A, Jones R; 11018 Study Investigators. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Oct;9(10):969-77. doi: 10.1016/S1474-4422(10)70194-0. Epub 2010 Aug 20. Review.

Iwamoto K, Ikeda K, Mizumura S, Tachiki K, Yanagihashi M, Iwasaki Y. Combined treatment of methylprednisolone pulse and memantine hydrochloride prompts recovery from neurological dysfunction and cerebral hypoperfusion in carbon monoxide poisoning: a case report. J Stroke Cerebrovasc Dis. 2014 Mar;23(3):592-5. doi: 10.1016/j.jstrokecerebrovasdis.2013.05.014. Epub 2013 Jun 19.

Berthier ML, Green C, Lara JP, Higueras C, Barbancho MA, Dávila G, Pulvermüller F. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol. 2009 May;65(5):577-85. doi: 10.1002/ana.21597.

Fugl-Meyer AR, Jääskö L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. Scand J Rehabil Med. 1975;7(1):13-31.

Duncan PW, Propst M, Nelson SG. Reliability of the Fugl-Meyer assessment of sensorimotor recovery following cerebrovascular accident. Phys Ther. 1983 Oct;63(10):1606-10.

Taub E, Miller NE, Novack TA, Cook EW 3rd, Fleming WC, Nepomuceno CS, Connell JS, Crago JE. Technique to improve chronic motor deficit after stroke. Arch Phys Med Rehabil. 1993 Apr;74(4):347-54.

van der Lee JH, Beckerman H, Knol DL, de Vet HC, Bouter LM. Clinimetric properties of the motor activity log for the assessment of arm use in hemiparetic patients. Stroke. 2004 Jun;35(6):1410-4. Epub 2004 Apr 15.

Uswatte G, Taub E, Morris D, Light K, Thompson PA. The Motor Activity Log-28: assessing daily use of the hemiparetic arm after stroke. Neurology. 2006 Oct 10;67(7):1189-94.

Collen FM, Wade DT, Bradshaw CM. Mobility after stroke: reliability of measures of impairment and disability. Int Disabil Stud. 1990 Jan-Mar;12(1):6-9.

Duncan PW, Wallace D, Lai SM, Johnson D, Embretson S, Laster LJ. The stroke impact scale version 2.0. Evaluation of reliability, validity, and sensitivity to change. Stroke. 1999 Oct;30(10):2131-40.

Kidd D, Stewart G, Baldry J, Johnson J, Rossiter D, Petruckevitch A, Thompson AJ. The Functional Independence Measure: a comparative validity and reliability study. Disabil Rehabil. 1995 Jan;17(1):10-4.

Starting date: January 2014
Last updated: May 19, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017